Blog

​January 2015: Eagle Biosciences Introduces New FGF23(C-Terminal) ELISA Assay

Nashua, NH:
Eagle Biosciences is now offering a new, robust multi-matrix FGF23(C-Terminal) ELISA Assay Kit. This assay was developed and manufactured by Biomedica Gruppe in Austria.
Biomedica has a strong focus on delivering consistent, top-notch, innovative cardiovascular
and bone metabolism immunoassays for researchers around the world.

The FGF23 (C-terminal) ELISA Assay kit has excellent sensitivity, great correlation with
existing ELISA methods, and utilizes a low sample volume. This analyte provides incredible value and unique
insights to research surrounding the regulation of bone and mineral
homeostasis. In addition, this kit not only offers the ability to measure FGF23
in a variety of sample types such as serum, plasma, urine, and cell culture but
also provides excellent stability in all matrices after sample collection.

“We are thrilled
to incorporate another unique Biomedica kit into our bone metabolism product line.” said Dan Keefe, President of EagleBio.
He continued, “This assay has so much to offer in terms of advantages
over other FGF23 kits currently in the market.
In fact, it is the only FGF23 assay that can be used for serum and plasma
and its excellent sensitivity provides clear
differentiation even at low serum FGF23 levels.”

This product
is currently for research use only and is available from Eagle Biosciences in Canada
only
. Check out the links below, visit the Eagle website, www.EagleBio.com,
or call 866-411-8023 for full details.

 

FGF23 ELISA

Biomarker Spotlight: ACTH (Adrenocorticotropic Hormone)

ACTH (Adrenocorticotropic Hormone) is secreted from corticotropes in the anterior lobe
of the pituitary gland in response to cortocotropin-releasing hormone (CRH)
released by the hypothalamus.

ACTH is an important component of
the hypothalamic-pituitary-adrenal (HPA) axis.
The HPA axis is critical in maintaining homeostasis under physical and
psychological stress by controling cortisol levels in the body and producing
ACTH in response to such stress.

ACTH stimulates secretion of
glucocorticoid steroid hormones from adrenal cortex cells, particularly in the
zona fasciculata of the adrenal gland. ACTH acts by binding to cell surface
ACTH receptors, which are located predominantly on adrenocortical cells of the
adrenal cortex.

 

Reasons to Measure
ACTH:
 

ACTH blood levels are measured to help detect abnormal cortisol concentrations
(elevated or deficient) in the body which can cause a variety of
diseases/conditions. Thus, ACTH
measurements are important for numerous diagnoses and consequential monitoring.

 

Increased Levels of
ACTH

1. Addison’s disease –

Primary adrenal insufficiency resulting from adrenal cortex
hyofunction/dysfunction, a deficient production of glucocoticoids, mineralocorticoids
and androgens, and with increased levels of both ACTH and plasma renin
activity.

 

2. Congenital adrenal hyperplasia (CAH)-

Endocrine system disease that can cause development of masculine traits in
female fetuses, otherwise known as virilization.

 

3. Cushing’s syndrome-

Endogenous
hypercortisolism, resulting from an excess in corticotropin (ACTH) secretion by
tumors in the pituitary gland or elsewhere. Symptoms include abnormal fat
distribution, predominantly in the supraclavicular and temporal fossae. Other symptoms or clinical presentations of
this condition, include proximal muscle fatigablility weakness, wide stretch
marks, easy bruising, and decreased linear growth coupled with continued weight
gain in a child.

 

4. Cushing’s disease-

Cushing’s disease is the most common form of endogenous
Cushing’s syndrome, caused by a tumor in the pituitary gland. This tumor is a build up of abnormal cells
that secrete ACTH in excessive amounts which in turn, induces adrenal glands to
produce too much cortisol and consequently causes the clinical manifestations
and symptoms as mentioned above for Cushing’s syndrome.

 

5. Muliple endocrine neoplasia (MEN), type I

A genetic, endocrine disease that
involves formation of a tumor or overactivity of one or more of the endocrine
glands such as the pancreas, parathyroid, or pituitary gland. Clinical manifestations vary depending on the
gland involved in the patient but can include all of the following:
hyperparathyroidism, hypercalcemia, pancreatic islet cell tumors, hypoglycemia, peptic
ulcers, and pituitary tumors.

 

Decreased Levels of
ACTH:

6. Hypopituitarism and/or secondary adrenal insufficiency

Secondary adrenal insuffiency is caused by impairment of the pituitary
gland or
or failure of the hypothalamus to stimulate pituitary ACTH production. Impairment/disease of the pituitary gland hinders the
release of ACTH and thus can distrupt several of your body’s important functions,
such as growth, blood pressure and reproduction.

 

7. Adrenal gland tumor

Cancerous or benign tumor of either of the adrenal glands, the adrenal
cortex or the adrenal medulla that can be functioning (overproduce hormones) or
non-functioning (does not produce hormones).

The adrenal cortex is the outer part of the
adrenal gland and it produces the steroid hormones: cortisol, aldosterone, and
dehydroepiandrosterone (DHEA). 
Tumors of the adrenal cortex are adenoma
(non-functioning) and adrenocortical carcinoma (functioning and non-functioning). 

The adrenal medulla is the inner part of the
adrenal gland and it produces three different hormones, also referred to as
catecholamines: epinephrine, norepinephrine, and dopamine. Tumors of the
adrenal medulla are neuroblastoma (functioning and non-functioning) and
pheochromocytoma (functioning).

Adrenal tumors can cause excessive production of cortisol thereby
decreasing the levels of ACTH. Symptoms
and clinical manifestations vary depending on the type and location of the
adrenal tumor (cortex or medulla).

 

8. Other tumors that produce cortisol

Tumors such as lung cancer, can produce ACTH which cause the
adrenal gland to overproduce steroid hormones:

  • Islet cell tumors of the pancreas
  • Small cell tumors of the lung and benign carcinoid tumors of
    the lung
  • Medullary carcinoma of the thyroid
  • Tumors of the thymus gland

ACTH producing tumors as mentioned directly above, cause Ectopic ACTH syndrome
which has similar but fewer symptoms than that of the classic Cus
hing’s syndrome.

 

 

References:

1. Betterle, C. et al. “Autoimmune Addison’s disease.” Endocrine Development 2011;20:161-72. doi: 10.1159/000321239.

2.Carney, J. A. “Familial multiple endocrine neoplasia syndromes: components, classification, and nomenclature.” Journal of Internal Medicine, 1998; 243: 425–432. doi: 10.1046/j.1365-2796.1998.00345.x

3. Chakrabarty, A. et al. “Correcting hypothalamic-pituitary-adrenal axis dysfunction using observer-based explicit nonlinear model predictive control,” Engineering in Medicine and Biology Society (EMBC), 2014 36th Annual International Conference of the IEEE: 3426-3429, doi: 10.1109/EMBC.2014.6944359

4. Charmandar, Evangelia et al. “Adrenal insufficiency.”The Lancet 2014; 383 (9935): 2152 – 2167. doi: 10.1016/S0140-6736(13)61684-0.

5. Dreger, A. et. al. “Prenatal Dexamethasone for Congenital Adrenal Hyperplasia: An Ethics Canary in the Modern Medical Mine.” Journal of Bioethical Inquiry 2012;9(3):277-294. doi:10.1007/s11673-012-9384-9.

6. Hershel, Raff et al. “Cushing’s syndrome: from physiological principles to diagnosis and clinical care.”The Journal of Physiology 2015; 1469-7793. doi: 10.1113/jphysiol.2014.282871

7. Massachusetts General Hospital. “Cushing syndrome.”2007. www.;mgh.harvard.edu

8. Nieman, Lynnette K. et al. “Evaluation and treatment of Cushing’s syndrome.”The American Journal of Medicine 2005; 118(12): 1340 – 1346.

9. PennState Hershey Medical Center. “Ectopic Cushing Syndrome.” 2013.

10. Prevedello, D. et al. “Diagnosing, managing Cushing’s Disease: a multidisciplinary overview.” Review of Endocrinology; 2009. 19-24.

11. Ten, S. et al. “Addison’s Disease.” The Journal of Clinical Endocrinology & Metabolism 2001; 86(7): 2909-2922. doi:10.1210/jcem.86.7.7636

 

Related Kits:

ACTH ELISA

January 21, 2015- Eagle Biosciences Shares Some New Publications Across Multiple EagleBio Assay Kit Product Lines

 

 

January 21, 2015- EagleBio offers numerous sensitive, solid, and esoteric kits in diverse areas of research in a variety of disciplines. 

Scientists continue to publish research for many EagleBio assays but we would like to highlight a handful of recent publications for select kits within our Oxidative Stress Assay Kits, Cancer Biomarker Kits, Catecholamine Assay Kits , and Immunology Assay Kits product lines. Check out the product pages for full information on the kits, or view the links below for the new publication details.

 

Creatinine Microplate Assay Kit

Publication:

Variation in Levels of the Lung Carcinogen NNAL and its Glucuronides in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer

 

CXCL 12 / SDF-1 Alpha ELISA

Publication:

CXCR4 promotes renal tubular cell survival in male diabetic rats: implications for ligand inactivation in the human kidney

 

Chromogranin A ELISA Kit

Publication:

Elevated Circulating Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Levels are Associated with Neuroendocrine Differentiation in Castration Resistant Prostate Cancer

 

BI-CAT Adrenaline & Noradrenaline ELISA Assay Kit

Publication:

Protective Effects of Hypothalamic Beta-Endorphin Neurons Against Alcohol-Induced Liver Injuries and Liver Cancers in Rat Animal Model

 

 

Serotonin ELISA Assay Kit

Publication:

Coagulation-Driven Platelet activation Reduces Cholestatic Liver Injury and Fibrosis in Mice

 

Rat Interferon Gamma (IFN-gamma) ELISA & Rat IL-10 ELISA KIT

Publication:

Attenuation of Renal Ischemia/Reperfusion Injury by Açaí Extract Preconditioning in a Rat Model

 

25-OH Vitamin D HPLC Assay Kit

Publication:

Assessment of Becton Dickinson Plain and Serum Separator Tubes in Measurement of 25-Hydroxyvitamin D3 (25OHD3) by HPLC and Immunoassay Methods

New Super Drug for Superbugs- 3 Major Reasons the Drug and the Process to Test it are Dire for Healthcare

 

 

Extremely resistant bacteria which can’t be killed by antibiotics, also known as Superbugs have become a growing threat to public health over the past several years. Scientists have recently discovered a new Super-Drug (Teixobactin)to combat these Superbugs through complex microbiological testing which involves growing bacteria in the soil.  

 

3 Reasons this Drug and New Microbiological Drug Testing is Needed:

 

1. World is at risk of entering a “post-antibiotic” era- formerly treatable infections could become deadly.

 

2.Developing new antibiotics has been a challenge scientifically and financially- this new testing to develop new drugs like Teixobactin has created enhanced conditions for bacteria to grow.

 

3. Teixobactin so far show no sign of evolving resistance- the bacteria killing properties of this drug attack bacteria in a way that no other drug has in the past.

 

 

READ MORE

 

*images from usatoday.com and knowabouthealth.com respectively

Top 10 Medical Innovations of 2015- Can We Really Predict Them?

 

It is fascinating to think about what 2015 has in store for medical science and technology.  Which are the up-and-coming technologies and which will have the biggest impact on health care in 2015?  

There is actually a annual conference sponsored by the Cleveland Clinic that focuses on identifying and selecting nominated medical innovations that meet a strict set of criteria.  Experts from the Cleveland Clinic team perform extensive research on each nomination and then present a final list to two panels of leading Cleveland Clinic physicians. These physicians then vote to decide the Top 10 Medical Innovations for the year. 

 Here’s what they selected for 2015:

1. Mobile stroke unit

2. Dengue fever vaccine

3. Painless blood testing

4. New way to lower cholesterol

5. Cancer drug that doesn’t harm healthy tissue

6. Immune booster for cancer patients

7. Wireless cardiac pacemaker

8. New medications for idiopathic pulmonary fibrosis

9. Single-dose radiation therapy for breast cancer

10. New drug for heart failure

Read More

Biomarker Spotlight: FGF-21

 

 


 

Fibroblast growth factor 21 (FGF-21) is a novel member  of the
FGF-19 subfamily, which includes FGF-19, FGF-21, and FGF-23. The FGF-19 family
members are potent endocrine hormones in the regulation of a diverse
physiological homeostasis. FGF-21 is mainly expressed in the liver and is an important modulator of not only glucose and lipid metabolism but also energy balance.

 

 

Structure Necessary
for Bioactive Processing:

 

The
induction of signaling by FGF21 is a complicated process which results from the
formation of a ternary complex between FGFR1c, β-Klotho and FGF21. FGFR1c can
remain inactive in close proximity to β-Klotho in the absence of FGF21. When
FGF21 and β-Klotho are bound together they are able to dimerize FGFR1c in a way
that allows the activation of signaling.
Recent studies have demonstrated that understanding this complex process
and the structural relationship has significant implications for the
development of biological therapeutics.

 

FGF21 is released by the liver into the bloodstream
and once in adipose tissue, it binds to its receptor (FGFR) forming a complex
with its co-receptor βKlotho. FGF21 then exerts its pleiotropic metabolic
effects through its actions on numerous targets, including adipose tissue,
liver, brain and pancreas. The expression of FGF21 is under the control of both
peroxisome proliferator-activated receptor gamma (PPARγ) and peroxisome
proliferator-activated receptor alpha (PPARα). FGF21 has been
identified as an important regulator of glucose, lipids, and energy balance.

 

Reasons to Measure FGF-21:

FGF-21 is a novel protein that has been identified as a useful biomarker for studying metabolic syndrome. Further research is needed for this analyte in order to better understand its precise pathophysiological role and its associated molecular pathways. Measuring FGF-21 may provide valuable insight for researchers in detecting, monitoring, and studying drug targets for a variety of individuals with various metabolic pathologies.

 

Diseases/conditions associated with elevated FGF-21 levels:

  • Muscle-Manifesting Mitochondrial Respiratory Chain Deficiencies
  • Nonalcoholic Fatty Liver Disease
  • Medical Conditions Related to Type 2 Diabetes
  • Gestational Diabetes
  • Obesity
  • Cushings Syndrome
  • Renal Disease

 

References and Relevant Publications:

1 .Cuevas-Ramos, Daniel, et al. “The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism.”Current Diabetes Reviews, 2009,5, 216-220. 

2 .Ge, Xuan et al. “Metabolic actions of FGF21: molecular mechanisms and therapeutic implications.” Diabetes and Obesity doi:10.1016/j.apsb.2012.06.011.

3 .Micanovic R, et al. “Different roles of N- and C- termini in the functional activity of FGF21.” J Cell Physiol. 2009 May;219(2):227-34.

4 .Potthoff, Matthew J. et al. “Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.”Genes & Develeopment

5. Smith, Richard et. al.“FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein.” Plos One: DOI: 10.1371/journal.pone.0061432

6. Suomalainen, Anu et. al. “FGF-21 as a Biomarker for Muscle Manifesting Mitochondrial Respiratory Chain Deficiencies: a Diagnostic Study. The Lancet Neurology 2011; 10:806-818.

7. Yie J, et al. FGF21 N- and C-termini Play Different Roles in Receptor Interaction and Activation. FEBS Letters. 2009 Jan 5;583:19-24. 

8. Yusuke, Murata,“FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology.” Journal of Nutrition and Metabolism; 2011: doi:10.1155/2011/981315

 

Related Kits:

FGF-21 ELISA

Smart Skin- Giant Step for Prosthetics

A prosthetic hand, covered with the prosthetic skin

New “Smart
Skin” may be the answer for prosthetic patients regaining their sense of touch
with their bionic limbs. In recent
experiments, researchers have coated prosthetic skin with electronics including
heating devices and sensors. This new
skin is remarkably sensitive and capable of sensing a wide variety of data in
a way that is so vastly similar to that of a real limb. This skin can detect such as
information as temperature, humidity, stretching and pressure. 


Over the past few years, many research groups around the globe have been
developing bionic arms and legs that could help patients replace lost limbs. They have been looking for ways to improve
upon these limbs striving to make them look and more importantly feel more
real. This new technology brings lots of hope but it also brings safety concerns as well.  There will be a lot more testing and trials involved but this would be a giant step for prosthetics and patients in need of them.  Read More

image above from www.livescience.com

​2014 -2015 Flu Shots: May have Reduced Effectiveness But Still Provides Protection


The flu season has
started to pick up and there is concern that the 2014- 2015 flu shot may not be
as effective as they had originally thought.
The Centers for Disease Control and Prevention (CDC) advised clinicians on
December 3rd that the major circulating strain this year has in fact
mutated to the point that the shots are providing reduced protection. Results from testing performed on positive
samples from October 1 through November 22, 2014 revealed that 48% were
antigenically like the 2014-2015 influenza A (H3N2) vaccine, but 52% were found to be different than this
year’s shot.
However, with that being said that does NOT mean the flu shot
is not worth getting as it still has been found to provide some protection against
drifted viruses and even though reduced, this cross-protection might reduce the likelihood of severe outcomes such
hospitalization and death
Read More 

​EagleBio Assay Kits in Several New Publications

 

EagleBio offers numerous unique and robust kits in a variety of emerging areas of research and disciplines. There are several publications to date for the assays but there some new publications to highlight for our Endocrine Assay Kits, Oxidative Stress Assay Kits, Cancer Biomarker Kits product lines. Check out the product pages for full information on the kits, or view the links below for the new publication details.

 

Mouse /
Rat GLP-1 Active (7-36) ELISA Kit

Publication:

The Pancreapedia: Exocrine Pancreas Knowledge Base

 

Rat Tissue Type Plasminogen Activator (TPA) Total ELISA Assay Kit

Publication:

Locally Increased Concentrations of Inflammatory Cytokines in an Experimental Intraabdominal Adhesion Model

 

Serotonin ELISA Assay Kit

Publication:

Combination Fluconazole/Paroxetine Treatment is Neuroprotective Despite Ongoing Neuroinflammation and Viral Replication in an SIV model of HIV Neurological Disease